The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Dendritic cell vaccine for MM: Trial updates with maintenance & checkpoint inhibitor pidilizumab
David Avigan, MD, of Harvard Medical School, Boston, MA, gives us an update on the promising results of the personalized dendritic cell vaccine being trialled in multiple centers for multiple myeloma (MM), as well as and acute leukemia (BMT CTN 1401; NCT02728102). Dr Avigan also highlights another study combining this vaccine with the PD1 checkpoint inhibitor pidilizumab (NCT01067287) that is running at his institution. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
